Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;7:50. doi: 10.1038/s41420-021-00434-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Immunoblots showing protein levels of NLRP3 (A1, A2), ASC (A1, A3), cleaved caspase-1 (A1, A4), and GSDMD-N (A1, A5) in the indicated groups. B Percentage of TUNEL-positive cells in the indicated groups. C Proportion of heart to body weight in the indicated groups. D Quantification of the cross-sectional area of cardiomyocytes of the left ventricle in the indicated groups. E Quantification of the myocardial fibrosis in the indicated groups. F Quantitative analysis of left ventricular EF in the indicated groups. G Immunoblots showing protein levels of NLRP3 (G1, G2), ASC (G1, G3), cleaved caspase-1 (G1, G4), and GSDMD-N (G1, G5) in the suitably treated cardiomyocytes. H Percentage of PI-positive cells in the suitably treated cardiomyocytes. I Measurement of the cell surface area of cardiomyocytes in the indicated groups. mRNA expression of cardiac hypertrophy markers BNP (J) and β-MHC (K) in the suitably treated cardiomyocytes. Results are presented as the mean ± SEM, n = 6. ^∗P < 0.01 compared to control, ^#P < 0.01 compared to TAC group or Ang-II group.